Comparing AIT Therapeutics (OTCMKTS:AITB) and Luminex (OTCMKTS:LMNX)

AIT Therapeutics (OTCMKTS:AITB) and Luminex (NASDAQ:LMNX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares AIT Therapeutics and Luminex’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AIT Therapeutics N/A N/A -$18.04 million ($3.01) -2.56
Luminex $334.64 million 3.50 -$3.84 million ($0.21) -123.33

Luminex has higher revenue and earnings than AIT Therapeutics. Luminex is trading at a lower price-to-earnings ratio than AIT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AIT Therapeutics and Luminex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AIT Therapeutics N/A N/A -100.76%
Luminex -1.18% -2.03% -1.74%

Insider and Institutional Ownership

81.7% of Luminex shares are held by institutional investors. 8.7% of Luminex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

AIT Therapeutics has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Luminex has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AIT Therapeutics and Luminex, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AIT Therapeutics 0 0 0 0 N/A
Luminex 1 1 1 0 2.00

Luminex has a consensus price target of $26.50, indicating a potential upside of 2.32%. Given Luminex’s higher probable upside, analysts plainly believe Luminex is more favorable than AIT Therapeutics.

Summary

Luminex beats AIT Therapeutics on 9 of the 12 factors compared between the two stocks.

About AIT Therapeutics

AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.